Mounjaro

The Anti-Obesity Doctor: If You Don't Exercise, This Is What's Happening To You! - Gabrielle Lyon

The Diary Of A CEO

Another GLP-1 agonist medication similar to Ozempic, used for obesity.

Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing

All-In Podcast

Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver

Andrew Huberman

A brand name for tirzepatide, a GLP-1 agonist (referred to as semaglutide version 2.0), used for type 2 diabetes and weight loss.

Tools for Nutrition & Fitness | Dr. Layne Norton

Andrew Huberman

A GLP-1 agonist, similar to Ozempic, used for weight loss by reducing appetite. People report significant weight loss with its use.

Dave Ricks, CEO of Eli Lilly | The All-In Interview

All-In Podcast

Eli Lilly's dual-acting drug, tirzepatide, targeting both GLP-1 and GIP receptors, showing significant results in weight loss and diabetes management.

How to Exercise & Eat for Optimal Health & Longevity | Dr. Gabrielle Lyon

Andrew Huberman

A dual GLP-1/GIP agonist medication for weight loss, offering potentially greater weight loss than Ozempic, with similar considerations for muscle preservation.

Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent [AMA 45 sneak peek]

Peter Attia MD

Branded name for tirzepatide, approved for type 2 diabetes and being considered for obesity.

How to Navigate Menopause & Perimenopause for Maximum Health & Vitality | Dr. Mary Claire Haver

Andrew Huberman

GLP-1 receptor agonist medications that can be important tools for patients with weight problems, leading to weight loss and reduced food noise, but requiring counseling on adequate protein intake and muscle loss prevention.

Transform Your Health by Improving Metabolism, Hormone & Blood Sugar Regulation | Dr. Casey Means

Andrew Huberman

Another GLP-1 receptor agonist mentioned in the context of appetite suppression and high cost.

I Tested 100,000 People's DNA. This Diet Will Kill You - Gary Brecka

The Diary Of A CEO

A GLP-1 inhibitor (Tirzepatide) that performed better in clinical trials than Semaglutide, with similar effectiveness and cautions for weight management.

337- Insulin resistance masterclass: The full body impact of metabolic dysfunction, treatment & more

Peter Attia MD